Spero Therapeutics
在场
Spero Therapeutics 是一家在股票代码 SPRO (US) 下上市的公司。
高管
查看带有其 13 名主要高管的组织结构图
Spero Therapeutics 搜索最多的简介
高管在Spero Therapeutics变化
- John Pottage, Director, 已经离开公司 (新闻发布的2024八月6号).
- Kamal Hamed, Chief Medical Officer, 将于 20248月29 退休 (新闻发布的2024八月6号).
创建提醒
跟踪 Spero Therapeutics 的高管变动
生物技术
Spero Therapeutics 拥有 2,337 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
- OraSure Technologies has announced the acquisition of Sherlock Biosciences (公布2024十二月20号).
- SiteOne Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Spero Therapeutics 的最新新闻稿
- Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020 | Spero Therapeutics, Inc.
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Spero Therapeutics, Inc.
- Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections | Spero Therapeutics, Inc.
- Spero Therapeutics to Present at Investor Conferences in September | Spero Therapeutics, Inc.
- Spero Therapeutics Announces Pricing of Securities Offering | Spero Therapeutics, Inc.
- Spero Therapeutics Announces Proposed Public Offering | Spero Therapeutics, Inc.
- Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis | Spero Therapeutics, Inc.
- Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720 | Spero Therapeutics, Inc.
- Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update | Spero Therapeutics, Inc.
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Spero Therapeutics, Inc.
- View more press releases Close
通过电子邮件
